The patient’s view of health care value
The U.S. health care system is undergoing a transformation in how it delivers and pays for care. As traditional fee-for-service gives way to value-based arrangements, understanding the “value” of health care has become a national priority. The National Health Council is focused on ensuring the voice of the patient and patient organizations are an integral part of the value discussion.
The NHC, with stakeholder input, has created a Value Model Rubric to help evaluate the patient centeredness of value models and to guide value model developers on the meaningful incorporation of patient engagement throughout their processes. Read it here.
A tool to assist patient group staff in preparing actionable written comments on a specific value assessment.
A list of recommendations developed by members of the patient community who have already gone through a value assessment. View it here.
What are the key characteristics of patient-centered value assessment? View the domains here.
A step-by-step guide for patient advocacy organizations to engage in discussions on and the assessment of value. Read it here.
Depiction of the process of incorporating patient-provided information into a value assessment and how the results might feed into decision-making about care options.
A collaboration between the University of Maryland School of Pharmacy, the NHC, patient community leaders, and payer and industry stakeholders. The Center strives to promote the inclusion of diverse patient voices in research to help uncover the elements of value in health care that are most important to patients.
Learn more here.
The Work Group currently has representatives from 35 patient groups with either prior direct experience with value assessment organizations. The Work Group is open to NHC patient-group members and non-member patient organizations by invitation.
On July 31, 2018, the National Health Council (NHC) convened representatives from US organizations that have produced value frameworks/assessments over the last several years with participants from patient groups that have interacted with those organizations. The objectives of the meeting were to:
- Articulate a shared vision for what marks success in enhanced patient centricity in value assessment (VA) and
- Outline tangible, feasible actions that can be taken to achieve that success. The actions may be on the part of patient groups, value-assessment organizations (VA bodies), or both in collaboration.
Read about the findings here.
Meetings & Events
Letters & Comments
Sponsors include: Novartis, Amgen, BIO, Biogen, Pfizer, PhRMA, Allergan